Fig. 2From: Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinomaTime to progression (TTP) survival curves of patients with unresectable hepatocellular carcinoma in the two groups. The median TTP in the Apatinib+TACE group was significantly longer than that of the TACE alone group (TTP: 6.3 months vs 3.5 months, P = 0.002)Back to article page